Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuedexta for Pseudobulbar Affect in Alzheimer's Disease
NCT01832350Phase 4Terminated
- Sponsor
- St. Joseph's Hospital and Medical Center
- Start
- Aug 2012
- Primary completion
- Dec 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dextromethorphan + quinidine in pseudobulbar affect (PBA), sponsored by St. Joseph's Hospital and Medical Center. Primary endpoint: Reduction of Pseudobulbar Affect frequency at 26 weeks. Started Aug 2012; status: terminated.
02
Drugs
dextromethorphan + quinidine
03
Conditions
pseudobulbar affect (PBA)
Beyond the preview
Go deeper on NCT01832350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01832350.